Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 4017

Next Previous
X
Search
Drug Profile

AZD 4017

Alternative Names: AZD4017

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; University of Birmingham
  • Class Amides; Antiglaucomas; Antihyperglycaemics; Carboxylic acids; Cyclohexanes; Obesity therapies; Piperidines; Pyridines; Small molecules; Sulfides
  • Mechanism of Action 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cushing syndrome; Pseudotumour cerebri
  • Discontinued Glaucoma; Obesity; Ocular hypertension; Type 2 diabetes mellitus

Most Recent Events

  • 17 Sep 2020 Phase II development is still ongoing for Cushing syndrome in United Kingdom (NCT03111810)
  • 27 Feb 2019 AstraZeneca completes a phase-II trial in Cushing's syndrome (In volunteers, Combination therapy) in United Kingdom (PO) (NCT03111810) (EudraCT2016-003060-40)
  • 18 Oct 2017 University of Leeds and Medical Research Council plan the phase II GC-SHealD trial for wound healing in patients with type 2 diabetes mellitus in United Kingdom (ISRCTN74621291) (NCT03313297)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top